- Home
- EYPT
as 11-15-2024 4:00pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 439.4M | IPO Year: | 2005 |
| Target Price: | $27.29 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.86 - $30.99 | Next Earning Date: | 11-07-2024 |
| Revenue: | $45,713,000 | Revenue Growth: | 7.50% |
| Revenue Growth (this year): | -3.01% | Revenue Growth (next year): | -66.81% |
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ANDO GORAN | EYPT | Director | Aug 21 '24 | Buy | $7.95 | 5,000 | $39,750.00 | 13,150 | |
| DICICCO WENDY F | EYPT | Director | Aug 20 '24 | Buy | $7.79 | 2,567 | $19,996.93 | 9,967 | |
| Zaderej Karen L. | EYPT | Director | Aug 19 '24 | Buy | $7.98 | 12,500 | $99,750.00 | 16,500 |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
TipRanks
5 days ago
EyePoint price target lowered to $33 from $38 at Baird
Simply Wall St.
8 days ago
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
10 days ago
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
10 days ago
EyePoint Pharmaceuticals: Q3 Earnings Snapshot
GlobeNewswire
10 days ago
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
Simply Wall St.
12 days ago
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing
GlobeNewswire
13 days ago
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.